Regentis Biomaterials Ltd. (RGNT) Stock Price & Analysis
Regentis Biomaterials Ltd. (RGNT) — MoonshotScore 63/100 (Fair band), calculated Oct 6, 2026. Price $1.73 (-6.41%), as of the Oct 5, 2026 trading session; market cap $12.2M.
Educational signal · not a buy or sell recommendation · How to read this
Regentis Biomaterials Ltd. · RGNT
Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions. Their lead product, GelrinC, targets painful knee injuries by utilizing a cell-free hydrogel implant to regenerate damaged cartilage.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Regentis Biomaterials (RGNT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Too few pillars have data for a confident read — treat the score as provisional. Business Quality: n/a; Financial Safety: Fortress; Valuation: n/a; Growth Durability: n/a; Momentum: Falling.
Holding back: weak price trend
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 63 | Fair | |
| 64 | Fair | |
| 64 | Fair | |
| 63 | Fair | |
| 63 | Fair | |
| 64 | Fair |
The score moved from 64 in the stored Oct 5, 2026 snapshot to 63 in the current publication computed Oct 6, 2026 (-1); the largest pillar moves were Momentum -1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.73 | |
| Change on the day | -6.41% | |
| 52-week range | $1.23 – $15.50 | |
| Market capitalisation | $12.2M | |
| Shares traded on the day | 83.7K |
Price & events
Other perspectives
Council score for Regentis Biomaterials (RGNT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Jun 14, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Jun 14, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the RGNT film — every key number, told as a short cinematic story
~2 min · open the film
What is Regentis Biomaterials (RGNT), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Regentis Biomaterials Ltd. (RGNT) is the company analyzed here. It employs 10 people and is led by Ehud Geller. The market values it at $12.2M.
What are the financial strengths and risks for Regentis Biomaterials (RGNT)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak price trend. Trailing ratios: current ratio 2.65.
How does Regentis Biomaterials compare with its peers?
Short answer
Regentis Biomaterials's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $406.48 Oct 5, 2026 | $144B | 94 5-pillar Oct 6, 2026 | |
| Regentis Biomaterials (RGNT) — this page | $1.73 | $12.2M | 63 |
| $10.60 Oct 6, 2026 | $62.7M | 51 5-pillar Oct 6, 2026 | |
| $10.37 Oct 6, 2026 | $74.7M | 44 5-pillar Oct 6, 2026 | |
| $1.94 Oct 6, 2026 | $15.5M | 40 5-pillar Oct 6, 2026 | |
| $0.70 Oct 5, 2026 | $20.8M | 40 5-pillar Oct 6, 2026 | |
| $3.02 Oct 6, 2026 | $138M | 38 5-pillar Oct 6, 2026 | |
| $4.41 Oct 6, 2026 | $48.8M | 37 5-pillar Oct 6, 2026 | |
| $3.57 Oct 6, 2026 | $39.4M | 33 5-pillar Oct 6, 2026 | |
| $1.11 Oct 6, 2026 | $48.8M | 29 5-pillar Oct 6, 2026 | |
| $8.51 Oct 6, 2026 | $38.3M | 26 5-pillar Oct 6, 2026 | |
| $0.36 Oct 6, 2026 | $32.0M | 23 5-pillar Oct 6, 2026 | |
| $0.91 Oct 6, 2026 | $5.61M | 20 5-pillar Oct 6, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Regentis Biomaterials (RGNT)?
What Investors Ask About Regentis Biomaterials (RGNT)
These answers are editorial: 1 of these 9 answers is drawn from the RGNT research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RGNT?
RGNT carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions.
Is RGNT a good stock to buy?
Stock Expert AI does not rate RGNT buy, sell or hold. Regentis Biomaterials Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RGNT stock price today?
The last price recorded on this page for Regentis Biomaterials Ltd. (RGNT) is $1.73, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for RGNT?
Regentis Biomaterials faces several key risks inherent to the biotechnology and medical device industries. These include the potential for regulatory setbacks or delays in clinical trials, which could impact the timeline for commercializing GelrinC.
What are the key factors to evaluate for RGNT?
Regentis Biomaterials Ltd. (RGNT) holds a MoonshotScore in the moderate range. Focus on GelrinC, a cell-free hydrogel implant, positions the company in the innovative area of tissue regeneration for knee injuries. Not financial advice.
How frequently does RGNT data refresh on this page?
RGNT's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RGNT's recent stock price performance?
Regentis Biomaterials Ltd. (RGNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Gelrin technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGNT overvalued or undervalued right now?
Regentis Biomaterials Ltd. (RGNT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGNT before investing?
Before investing in Regentis Biomaterials Ltd. (RGNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (11 figures)
The 11 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 5 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.73 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T17:14:44.178Z. | |
px.change | Change on the day | -6.41% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $12.2M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T17:03:55.000Z. Captured from FMP at 2026-10-05T17:14:43.166Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.1186 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 83.7K | FMP | Financial Modeling Prep (FMP) · quote |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $1.23 – $15.50 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
id.employees | Employees | 10 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
id.ceo | Chief executive | Ehud Geller | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 2.65 | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 63 of 100 · Fair · pillars n/a / 100 / n/a / n/a / 15 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 64 (stored snapshot Oct 5, 2026) → 63 (current publication computed Oct 6, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.